Genzyme Corporation
                                                      One Kendall Squre
                                                      Cambridge, Ma 02139-1562
     Genzyme                                          617-252-7500
     Diagnostics                                      Fax 617-374-7300

                           Supply Agreement

        This Agreement, effective as of the 10th day of July, 1996 ("the 
        Effective Date"), by and between:

         CISTRON BIOTECHNOLOGY, INC. a corporation organized and 
         existing under the laws of the State of Delaware, USA and 
         having its principal place of business at Box 2004, 10 
         Bloomfield Avenue, Pine Brook, New Jersey, USA 07058 
         (hereinafter referred to as "CISTRON"),

                        and

        GENZYME CORPORATION, a corporation organized and existing 
        under the laws of the Commonwealth of Massachusetts, USA, 
        and having its principal place of business at One Kendall 
        Square, Cambridge, Massachusetts, USA 02139-1562 
        (hereinafter referred to as "GENZYME")

    WHEREAS, CISTRON has developed and is selling to the research market a 
    human interleukin -1 beta (IL-1b) research assay product, "HS Kit" (as 
    defined below);

    WHEREAS, GENZYME desires to purchase the HS Kit from Cistron for 
    resale;
        
    NOW THEREFORE, in consideration of the rights, obligations, and mutual 
    premises set forth herein, CISTRON and GENZYME, intending to be bound 
    thereby, agree as follows:

                                Article 1. Definitions
        
        The following terms as used in this Agreement shall have meanings set 
        forth in this Article.

        1.1  "Territory" shall mean the Research Market for all countries of 
        the world.
 
        1.2  "HS KIT" shall mean the following finished, but unlabelled, 
        components of CISTRON's human interleukin-1 beta assay (catalog 
        03-HS96) 

          1 Monoclonal antibody coated 96 well strip microtiter plate, 
          foil sealed

          1 Vial of recombinant interleukin-1 beta standard (lyophilized, 
          50 ng/mL after reconstitution)

          1 Vial of interleukin-1 beta polyclonal antibody (lyophilized, 
          11 mL after reconstitution)

          1 Bottle of  conjugate (liquid, .2mL


                                        40
<PAGE>



1.3  "AGREEMENT PERIOD" shall mean the calendar time period commencing 
with the date of the execution of this Agreement and extending for 
twenty-four (24) months therefrom.

1.4  "CONFIDENTIAL INFORMATION" - shall mean any proprietary 
information or materials belonging to the disclosing party 
(whether or not patentable) including, but not limited to, 
formulations, techniques, methodology, equipment, data, reports, 
know-how, sources of supply, patent positioning, consultants and 
business plans, including any negative developments, which are 
communicated to, learned by, or otherwise acquired by the party 
receiving such information or materials during or in the course of 
this Agreement, further including information concerning the 
existence, scope or activities of any research and development 
project of the disclosing party.

Notwithstanding the foregoing, CONFIDENTIAL INFORMATION shall not 
include an information which (i) is or becomes part of the public 
domain through no act or omission of the part of the receiving 
party, (ii) is disclosed to a third party by the disclosing party 
without restriction of disclosure by such third party, (iii) is in 
the receiving party's possession, without actual or constructive 
knowledge of an obligation to the confidentiality with respect 
thereto, at or prior to the time of disclosure under this 
Agreement, (iv) is disclosed to the receiving party by a third 
party having no obligation of confidentiality with respect 
thereto, (v) is released from confidential treatment by written 
consent of the disclosing party.

                  Article 2. Supply Agreement

2.1  During the AGREEMENT PERIOD, GENZYME agrees to purchase from 
CISTRON and CISTRON agrees to supply to GENZYME HS KITs for resale 
in the TERRITORY under GENZYME's name.

2.2  CISTRON agrees to manufacture and supply HS KITs to GENZYME at the 
following prices:

Quarterly GENZYME 		Sale Price/Kit to GENZYME
Purchases
less than 125 kits		$255 each plus freight and insurance
125-175				$220 each plus freight and insurance
176-300				$210 each plus freight and insurance
251-300				$190 each plus freight and insurance
301+                            $180 each plus freight and insurance

2.3  GENZYME will provide buffers for each HS KIT, label the HS KITs 
and components as GENZYME products, and provide product literature 
for inclusion in each HS KIT.
2.4  All orders from GENZYME will be subject to acceptance, by CISTRON. 
All purchases pursuant to orders by GENZYME shall be, at CISTRON's 
option, F.O.B. Pine Brook, New Jersey, U.S.A. or other place of 
manufacture. Title to, and risk of loss of and damage to, any 
shipments of the HS KITs shall pass to GENZYME when such HS KITs 
are delivered

                                    41
<PAGE>

at any F.O.B. location to a carrier of CISTRON's choice, if a carrier has
not been specified by GENZYME in this written order confirmation.

2.5  CISTRON will ship to GENZYME the quantity of kits ordered in a 
quarterly purchase order within forty-five (45) days of receipt of 
such purchase order and will invoice GENZYME. GENZYME shall pay 
each invoice in accordance with its regular terms of payment net 
thirty (30) days. CISTRON will, whenever possible, ship complete 
orders, however, should CISTRON not be able to ship a complete 
order, CISTRON will so notify GENZYME.  GENZYME may accept or 
refuse partial shipments at its discretion, but may not refuse 
acceptance of shipments that comprise at least 80% of a complete 
order.

2.6  CISTRON will perform quality control testing on each lot of HS 
KITs and provide such manufacturing an quality control 
information, on a confidential basis, to GENZYME as may be 
mutually agreed as necessary with each new production lot.  
GENZYME will keep such information confidential and will restrict 
its use solely to the HS KITs.

2.7  GENZYME shall perform in-house testing, at its own expense, as it 
deems appropriate upon receipt of each product shipment from 
CISTRON. GENZYME will report any product performance deficiencies 
or quality discrepancies GENZYME may discover to CISTRON within 
fifteen (15) days of receipt. Failure to report any product 
deficiencies or discrepancies with fifteen (15) days of the 
receipt of each product shipment shall constitute acceptance of 
the shipment.  If GENZYME notifies CISTRON within fifteen (15) 
days of its receipt of HS KITs that a kit or kits fail to meet 
specifications, such non-conforming kits which are due to a defect 
of one or more of the components supplied by CISTRON pursuant to 
paragraph 1.1 shall be replaced by CISTRON as soon as reasonable 
possible thereafter and, if already paid for, at CISTRON's cost.

2.8  CISTRON warrants merchantability of HS KITs only for use as a 
research product and only when used in conformance with the 
CISTRON HS KIT protocol.  Except as provided therein, CISTRON 
makes no warranty of merchantability or performance after 
acceptance of each shipment by GENZYME.  CISTRON specifically 
advises against the testing of human serum with the HS KIT, and 
GENZYME specifically agrees that CISTRON makes no warranty of 
performance of HS KITs run with human serum samples.

2.9  Any term or condition in a invoice or other document used by 
CISTRON which is different than the terms of this Agreement shall 
be deemed inapplicable.

2.10  CISTRON agrees not to enforce any of its patent rights against 
GENZYME and its distributors relating to GENZYME's marketing of HS 
KITs pursuant to the terms of this Agreement.  However, nothing 
contained herein shall be construed as granting or implying any 
right to GENZYME under any existing or future letters patent 
covering the  HS KIT.

                    Article 3. Warranties

3.1  Each of CISTRON and GENZYME warrants and represents to the other 
that it has the full right and authority to enter into this 
Agreement.
                                      
                                    42
<PAGE>

3.2  THE WARRANTIES SET FORTH IN THIS ARTICLE 3 AND IN 2.8 ARE THE ONLY 
WARRANTIES MADE BY THE PARTIES AND ARE EXPRESSLY IN LIEU OF ANY 
AND ALL OTHER WARRANTIES EXPRESSED OR IMPLIED INCLUDING, WITHOUT 
LIMITATION, ANY AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS 
FOR A PARTICULAR PURPOSE.  NOTWITHSTANDING ANYTHING STATED HEREIN 
TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE 
OTHER PARTY OR TO ANY DISTRIBUTEE OF THE OTHER PARTY OR ANYONE 
ELSE IN PRIVITY WITH THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, OR 
CONSEQUENTIAL DAMAGES REGARDLESS OF WHETHER OR NOT THE FIRST PARTY 
HAS BEEN APPRISED OF THE POSSIBILITY THEREOF.


                   Article 4.  Termination

4.1  Unless earlier terminated pursuant to paragraphs 4.2, 4.3, or 4.4,
this Agreement will expire two (2) years from the effective date 
set forth above.

4.2  Upon material breach of this Agreement by either party and in the 
event the breach is not cured within forty-five (45) days after 
written notice to the defaulting party by the other party, in 
addition to any other remedy it may have, the notifying party at 
its sole option may terminate this Agreement.

4.3  This Agreement may be terminated by either party if the other 
party becomes insolvent, makes an assignment for the benefit of 
its creditors, files a petition for protection under any 
bankruptcy law or consents to the appointment of a receiver of 
liquidation of its assets, or its ownership substantially changes.

4.4  This Agreement may be terminated by either party upon learning of 
the existence of a third party patent, which in the opinion of 
competent legal counsel is infringed by the sale of an HS KIT.

4.5  Upon any termination of the Agreement, GENZYME will be entitled to 
sell any completed inventory of HS KITs covered by this Agreement 
which remain on hand as of the date of the termination, so long as 
GENZYME pays to CISTRON the amount applicable to said purchase in 
accordance with the same terms and conditions as set forth in this 
Agreement.

4.6  Upon termination of this Agreement for any reason, nothing herein  
will be construed as releasing either party from any obligation 
that matured prior to termination of this Agreement.

                Article 5.  Publicity and Confidentiality

5.1  Neither party shall use the name of the other in any form of 
advertising or promotion without the prior written approval of the 
other.

5.2  (a) Except as provided in Section 5.2(b) below, for a period of 
five (5) years from the termination date of this Agreement, 
GENZYME will maintain any and all of the CONFIDENTIAL INFORMATION  
received from CISTRON, in confidence, will not use same for its 
own benefit except as expressly provided in this Agreement, and 
will not

                                    43
<PAGE>

release or disclose any tangible or intangible component
thereof to any third party without first receiving the prior 
written consent of CISTRON to said release or disclosure.

(b)  The provisions of Section 5.2(a) notwithstanding, GENZYME may 
disclosed  CONFIDENTIAL INFORMATION  of CISTRON to GENZYME 
Affiliates or in the event of a disclosure compelled by a court of 
competent jurisdiction.  In addition, GENZYME may disclose 
CONFIDENTIAL INFORMATION of CISTRON in confidence to any third 
party who has a need to know such CONFIDENTIAL INFORMATION for the 
purpose of this Agreement; provided that GENZYME will first notify 
CISTRON of the identity of such third party and that such 
disclosure will be made under the provisions of a written 
confidential disclosure agreement which is binding upon such third 
party to the same obligations of confidentiality under which 
GENZYME is bound to CISTRON by the terms of this Agreement.  
GENZYME need not notify CISTRON before disclosing any CONFIDENTIAL 
INFORMATION to any GENZYME Affiliate.

5.3  (a) For a period of five (5) years from the termination date of 
this Agreement, CISTRON will maintain any and all of the 
CONFIDENTIAL INFORMATION received from GENZYME, in confidence, 
will not use same for its own benefit except as expressly provided 
in this Agreement, and will not release or disclose any tangible 
or intangible component thereof to any third party, except for the 
purposes of this Agreement and only after prior notice to GENZYME 
and after obtaining a written confidential disclosure agreement 
binding such third party to the same obligation of confidentiality 
to which CISTRON is bound to GENZYME under this Agreement.

(b)  The provisions of Section 5.3(a) notwithstanding, CISTRON may 
disclose CONFIDENTIAL INFORMATION of GENZYME to CISTRON Affiliates 
or in the event of a disclosure compelled by a court of  competent 
jurisdiction.  In addition, CISTRON may disclose CONFIDENTIAL 
INFORMATION of GENZYME in confidence to any third party who has a 
need to know such CONFIDENTIAL INFORMATION for the purpose of this 
Agreement; provided that CISTRON will first notify GENZYME of the 
identity of such third party and that such disclosure will be made 
under the provisions of a written confidential disclosure 
agreement which is binding upon such third party to the same 
obligations of confidentiality under which CISTRON is bound to 
GENZYME by the terms of this Agreement.  CISTRON need not notify 
GENZYME before disclosing any CONFIDENTIAL INFORMATION to any 
CISTRON Affiliated.
                        
                   Article 6. General Provisions

6.1  The relationship between CISTRON and GENZYME is that of 
independent contractors. CISTRON and GENZYME are not joint 
venturers, partners, principal and agent, master and servant, 
employer and employee, and have no relationship other than as 
independent contracting partners.  CISTRON will have no power to 
bind or obligate GENZYME in any manner, other than as is expressly 
set forth in this Agreement. Likewise, GENZYME will have no power 
to bind or obligate CISTRON in any manner, except as is expressly 
set forth in this Agreement.

6.2  Any disagreement between the parties which relates to this 
Agreement will be submitted to arbitration by a single, mutually 
acceptable arbitrator to resolve such disagreement.  The 
arbitrator will conduct the arbitration in accordance with the 
Rules of the American

                                    44
<PAGE>

Arbitration Association, unless the parties agree otherwise.  If the parties
are unable to agree on the selection of an arbitrator, the arbitrator will
be selected in accordance with the procedures of the American Arbitration 
Association.  The decision and award rendered by the arbitrator will be final
and binding.  Judgment upon the award may be entered in any court having
jurisdiction thereof.

6.3  This Agreement sets forth the entire agreement and understanding 
between parties as to the subject matter thereof and supersedes 
all prior Agreements to this respect. There will be no amendments 
or modifications to this Agreement, except by a written document 
which is signed by both parties.

6.4  This Agreement will be construed and enforced in accordance with 
the laws of the State of New York without reference to its choice 
of law principles.

6.5  The headings in this Agreement have been inserted for convenience 
of reference only and are not intended to limit or expand on the 
meaning of the language contained in the particular article or 
section.

6.6  any delay in enforcing a party's rights under this Agreement or 
any waiver as to a particular default or other matter will not 
constitute a waiver of a party's right to future enforcement of 
its rights under this Agreement, excepting only as to any 
expressed written and signed waiver as to a particular matter for 
a particular period of time.

6.7  Any notice given pursuant to this Agreement will be in writing and 
will be deemed delivered upon the earlier of (i) the date of 
facsimile transmission or hand delivery, (ii) when received at the 
address set forth below, (iii) five (5) business days after mailed 
postage prepaid and properly addressed, with return receipt 
requested.

Notice will be delivered to the respective parties as indicated:

To GENZYME:		GENZYME Corporation
                        One Kendall Square
                        Cambridge,  Massachusetts 02139-1562
                        Attn: David Fleming

Copy to:		Legal Department
                        One Kendall Square
                        Cambridge, Massachusetts 02139-1562

To CISTRON:		CISTRON Biotechnology, Inc.
                        Box 2004
                        10 Bloomfield Avenue
                        Pine Brook, New Jersey USA 07058
                        Attn: President

Copy to:		Epstein Becker & Green, P.C.
                        250 Park Avenue
                        New York, New York USA 10177-0077
                        Attn: Sidney Todres, Esq.

                                    45
<PAGE>

6.8  Each party hereto will be excused from performance for failure or 
delay in meeting any obligations hereunder due to Acts of God, 
acts of war, fire, flood, embargo, riots or revolution, provided 
that such excusal from performance will last only for so long as 
that party's performance is reasonably prevented by such force 
majeure.  The party affected by such force majeure shall use its 
reasonable best efforts to mitigate any damage thus occasioned.

6.9  The provisions of this Agreement are severable and in the event 
that any provision of this Agreement shall be determined to be 
invalid or unenforceable such invalidity or unenforcability shall 
not in any way affect the validity or enforcability of the 
remaining provisions hereof.

IN  WITNESS WHEREOF, the parties have 
executed this Agreement as of the date first written above.

ACCEPTED AND AGREED TO:

CISTRON                                                GENZYME

By: /s/ BRUCE C. GALTON                 By: /s/DAVID FLEMING
    -------------------                     ----------------
    Bruce C. Galton                         David Fleming

Title: President & COO, Cistron         Title: President, Genzyme Diagnostics
       President                               President Diagnostics          
Date: 7-15-96                                  Date: July 11, 1996 
                                    46
<PAGE>